• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of mimotope vaccine against HIV-1

Research Project

Project/Area Number 13670463
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 内科学一般
Research InstitutionKumamoto University

Principal Investigator

MATSUSHITA Shuzo  Kumamoto University, Center for AIDS Research, Professor, エイズ学研究センター, 教授 (00199788)

Project Period (FY) 2001 – 2003
Project Status Completed (Fiscal Year 2003)
Budget Amount *help
¥3,700,000 (Direct Cost: ¥3,700,000)
Fiscal Year 2003: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2002: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
KeywordsHIV vaccine / mimotope / neutralizing antibody / phage library / HIV-1
Research Abstract

Development of an effective vaccine against Human Immunodeficiency Virus Type 1 (HIV-1) has been one of the most important research projects. We established a neutralizing monoclonal antibody, RC25 that was cross-reactive against approximately 60 % of claid B isolates of HIV-1. Using immuno-affinity chromatography conjugated with RC25 we successfully isolated 110 phage clones that specifically interacted with RC25. Six phage clones (NSV, APE, APS, SDF, YPW, YPL) were selected by detecting cross-reactivity to the other neutralizing antibodies of different specificity. These clones don t have an exact epitope (IGPXRA) associated with the binding of RC25. Instead, these peptides have mimotopes that resemble the antigenic structure(s) of gp120. However, immunization of animals with the synthetic peptides corresponded to the individual mimotope did not induce antibodies that could react and neutralize HIV. Because we thought that the antigenic structure of individual phage clone was broken in corresponding synthetic peptides we attempted to immunize rabbits with the phage clone itself. Weak but distinct reactivity and neutralizing activity of antibody induced by the immunization was observed for SF162. After screening several hundred clones we have focused on the 7 phage clones as the candidates for the minotopes. But none of them seemed to be ideal. Induction of broadly reactive neutralizing antibodies is deemed essential for the effective vaccine against HIV. Continuous effort for the development of antigen that induce cross-neutralizing antibodies should be supported with high priority.

Report

(4 results)
  • 2003 Annual Research Report   Final Research Report Summary
  • 2002 Annual Research Report
  • 2001 Annual Research Report
  • Research Products

    (31 results)

All Other

All Publications (31 results)

  • [Publications] Yoshimura, K.: "The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV_<89.6P>."J.Virol.Methods.. 121. 121-128 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Koito, A.: "Susceptibility of mink (Musteravision)-derived cells to replication by human immunodeficiency virus type-1."J.Virol.. 77. 5109-5117 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Koito, A.: "Ability of small animal cells to support post integration phase of human immunodeficiency virus type 1 replication"Virology. 305. 181-191 (2003)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Kimura, T.: "Reconstitution of spontaneous neutralizing antibody response against autologous HIV-I in chronically infected patients during highly active antiretroviral therapy."J.Infectious Diseases. 185. 53-60 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Wang, FX: "Emergence of autologous neutralization-resistant variants _from pre existing quasi species during viral-rebound of human immunodeficency virus type-1 infected patients under treatment of highly active anti retroviral therapy (HAART)."J.Infectious Diseases. 185. 608-617 (2002)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Yoshimura, K: "The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV89.6P"J.Virol.Methods.. 112. 121-128 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Koito, A.: "Susceptibility of mink (Musteravision)-derivedcells to replication by human immunodeficiency virus type-1."J.Virol.. 77. 5109-5117 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Koito, A.: "Ability of small animal cells to support post integration phase of human immunodeficiency virus type 1 replication"Virology. 305. 181-191 (2003)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Matsushita S: "Reconstitution of autologous isolate neutralizing antibodies under HAART and emergence of neutralization escape mutants in vivo."XIV International AIDS Conference 2002 (ed. Monduzzi Editore). 159-167 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Kimura, T.: "Reconstitution of spontaneous neutralizing antibody response against autologous HIV-1 in chronically infected patients during highly active antiretroviral therapy."J.Infect.Dis.. 185. 53-60 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Wang, F.X.: "Emergence of autologous neutralization-resistant variants from pre existing quasi species during viral-rebound of human immunodeficiency virus type-1 infected patients undertreatment of highly active anti retroviral therapy (HAART)."J.Infect.Dis.. 185. 608-617 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Yoshimura, K.: "The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV_<89.6P>"J.Virol.Methods.. 121. 121-128 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Koito, A: "Susceptibility of mink (Musteravision)-derived cells to replication by human immunodeficiency virus type-1"J.Virol.. 77. 5109-5117 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Koito, A: "Ability of small animal cells to support post integration phase of human immunodeficiency virus type 1 replication"Virology. 305. 181-191 (2003)

    • Related Report
      2003 Annual Research Report
  • [Publications] Kimura, T: "Reconstitution of spontaneous neutralizing antibody response against autologous HIV-1 in chronically infected patients during highly active antiretroviral therapy"J.Infectious Diseases. 185. 53-60 (2002)

    • Related Report
      2003 Annual Research Report
  • [Publications] Wang, FX: "Emergence of autologous neutralization-resistant variants from pre existing quasi species during viral-rebound of human immunodeficency virus type-1 infected patients under treatment of highly active anti retroviral therapy (HAART)"J.Infectious Diseases. 185. 608-617 (2002)

    • Related Report
      2003 Annual Research Report
  • [Publications] Matsushita, S: "Advance in treatment strategy and immune reconstruction against HIV-1 infection"Microbiol.Immunol.. 46. 231-239 (2002)

    • Related Report
      2003 Annual Research Report
  • [Publications] Matsushita, S: "XIV International AIDS Conference 2002"Monduzzi Editore. 8 (2002)

    • Related Report
      2003 Annual Research Report
  • [Publications] Koito, A: "Susceptibility of mink (Mustera vision)-derived cells to replication by human immunodeficiency virus type-1"J. Virol.. (in press). (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Koito, A: "Ability of small animal cells to support post integration phase of human immunodeficiency virus type 1 replication"Virology. 305. 181-191 (2003)

    • Related Report
      2002 Annual Research Report
  • [Publications] Kimura, T: "Reconstitution of spontaneous neutralizing antibody response against autologous HIV-1 in chronically infected patients during highly active antiretroviral therapy"J. Infectious Diseases. 185. 53-60 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Wang, FX: "Emergence of autologous neutralization-resistant variants from pre existing quasi species during viral-rebound of human immunodeficency virus type-1 infected patients under treatment of highly active anti retroviral therapy (HAART)"J. Infectious Diseases. 185. 608-617 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Matsushita, S: "Advance in treatment strategy and immune reconstruction against HIV-1 infection"Microbiol. Immunol.. 46. 231-239 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Ikegawa, M: "Elevated plasma stromal cell-derived factor 1 protein level in the progression of HIV type 1 infection/AIDS"AIDS Res. Hum. Retroviruses. 17. 587-595 (2001)

    • Related Report
      2002 Annual Research Report
  • [Publications] Matsushita, S: "XIV International AIDS Conference 2002"Monduzzi Editore. 8 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Wang FX: "Emergence of Autologous Neutralization-Resistant Variants from Preexisting Human Immunodeficlency Virus (HIV) Quasi Species during Virus Rebound in HIV Type 1-Infected Patients Undergoing Highly Acttve Antiretroviral Therapy"J Infect Dis. 185. 608-617 (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kimura T: "Reconstitution of Spontaneous Neutralizing Antibody Response against Autologous Human Immunodeficiency Virus during Highly Active Antiretroviral Therapy"J Infect Dis. 185. 53-60 (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] Ikegawa M: "Elevated plasma SDF-1 protein level in the progression of HIV-1 infection/AIDS"AIDS Res.Hum.Retrov. 17. 587-595 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Murakami T: "Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and toxoplasma infection"Internal Medicine. 39. 1111-1114 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] Matsushita S: "Current status and future issues in the treatment of HIV-1 infection"Int J Hematol. 72. 20-27 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] Tugarinov V: "NMR structure of an anti gp-120 antibody complex with a V3-peptide reveals a surface important for co-receptor binding"Structure. 8. 385-395 (2000)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi